[1] F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians, 68 (2018) 394-424.
[2] J. Alfred Witjes, T. Lebret, E.M. Comperat, N.C. Cowan, M. De Santis, H.M. Bruins, V. Hernandez, E.L. Espinos, J. Dunn, M. Rouanne, Y. Neuzillet, E. Veskimae, A.G. van der Heijden, G. Gakis, M.J. Ribal, Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer, Eur Urol, 71 (2017) 462-475.
[3] T.W. Flaig, P.E. Spiess, N. Agarwal, R. Bangs, S.A. Boorjian, M.K. Buyyounouski, T.M. Downs, J.A. Efstathiou, T. Friedlander, R.E. Greenberg, K.A. Guru, N. Hahn, H.W. Herr, C. Hoimes, B.A. Inman, M. Jimbo, A.K. Kader, S.M. Lele, J.J. Meeks, J. Michalski, J.S. Montgomery, L.C. Pagliaro, S.K. Pal, A. Patterson, D.P. Petrylak, E.R. Plimack, K.S. Pohar, M.P. Porter, M.A. Preston, W.J. Sexton, A.O. Siefker-Radtke, J. Tward, G. Wile, A. Johnson-Chilla, M.A. Dwyer, L.A. Gurski, NCCN Guidelines Insights: Bladder Cancer, Version 5.2018, J Natl Compr Canc Netw, 16 (2018) 1041-1053.
[4] V. Dadhania, M. Zhang, L. Zhang, J. Bondaruk, T. Majewski, A. Siefker-Radtke, C.C. Guo, C. Dinney, D.E. Cogdell, S. Zhang, S. Lee, J.G. Lee, J.N. Weinstein, K. Baggerly, D. McConkey, B. Czerniak, Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use, EBioMedicine, 12 (2016) 105-117.
[5] A. Kamoun, A. de Reynies, Y. Allory, G. Sjodahl, A.G. Robertson, R. Seiler, K.A. Hoadley, C.S. Groeneveld, H. Al-Ahmadie, W. Choi, M.A.A. Castro, J. Fontugne, P. Eriksson, Q. Mo, J. Kardos, A. Zlotta, A. Hartmann, C.P. Dinney, J. Bellmunt, T. Powles, N. Malats, K.S. Chan, W.Y. Kim, D.J. McConkey, P.C. Black, L. Dyrskjot, M. Hoglund, S.P. Lerner, F.X. Real, F. Radvanyi, G. Bladder Cancer Molecular Taxonomy, A Consensus Molecular Classification of Muscle-invasive Bladder Cancer, Eur Urol, 77 (2020) 420-433.
[6] N. van Dijk, S.A. Funt, C.U. Blank, T. Powles, J.E. Rosenberg, M.S. van der Heijden, The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer, Eur Urol, 75 (2019) 435-444.
[7] J. Jung, H. Zeng, T. Horng, Metabolism as a guiding force for immunity, Nat Cell Biol, 21 (2019) 85-93.
[8] L.A. O'Neill, R.J. Kishton, J. Rathmell, A guide to immunometabolism for immunologists, Nat Rev Immunol, 16 (2016) 553-565.
[9] B. Zhang, S. Horvath, A general framework for weighted gene co-expression network analysis, Statistical applications in genetics and molecular biology, 4 (2005) Article17.
[10] T. Davoli, H. Uno, E.C. Wooten, S.J. Elledge, Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy, Science (New York, N.Y.), 355 (2017).
[11] D. Lindgren, A. Frigyesi, S. Gudjonsson, G. Sjodahl, C. Hallden, G. Chebil, S. Veerla, T. Ryden, W. Mansson, F. Liedberg, M. Hoglund, Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome, Cancer Res, 70 (2010) 3463-3472.
[12] M. Riester, J.M. Taylor, A. Feifer, T. Koppie, J.E. Rosenberg, R.J. Downey, B.H. Bochner, F. Michor, Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer, Clin Cancer Res, 18 (2012) 1323-1333.
[13] W. Choi, S. Porten, S. Kim, D. Willis, E.R. Plimack, J. Hoffman-Censits, B. Roth, T. Cheng, M. Tran, I.L. Lee, J. Melquist, J. Bondaruk, T. Majewski, S. Zhang, S. Pretzsch, K. Baggerly, A. Siefker-Radtke, B. Czerniak, C.P. Dinney, D.J. McConkey, Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy, Cancer Cell, 25 (2014) 152-165.
[14] R. Seiler, H.A.D. Ashab, N. Erho, B.W.G. van Rhijn, B. Winters, J. Douglas, K.E. Van Kessel, E.E. Fransen van de Putte, M. Sommerlad, N.Q. Wang, V. Choeurng, E.A. Gibb, B. Palmer-Aronsten, L.L. Lam, C. Buerki, E. Davicioni, G. Sjodahl, J. Kardos, K.A. Hoadley, S.P. Lerner, D.J. McConkey, W. Choi, W.Y. Kim, B. Kiss, G.N. Thalmann, T. Todenhofer, S.J. Crabb, S. North, E.C. Zwarthoff, J.L. Boormans, J. Wright, M. Dall'Era, M.S. van der Heijden, P.C. Black, Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy, Eur Urol, 72 (2017) 544-554.
[15] S. Mariathasan, S.J. Turley, D. Nickles, A. Castiglioni, K. Yuen, Y. Wang, E.E. Kadel, III, H. Koeppen, J.L. Astarita, R. Cubas, S. Jhunjhunwala, R. Banchereau, Y. Yang, Y. Guan, C. Chalouni, J. Ziai, Y. Senbabaoglu, S. Santoro, D. Sheinson, J. Hung, J.M. Giltnane, A.A. Pierce, K. Mesh, S. Lianoglou, J. Riegler, R.A.D. Carano, P. Eriksson, M. Hoglund, L. Somarriba, D.L. Halligan, M.S. van der Heijden, Y. Loriot, J.E. Rosenberg, L. Fong, I. Mellman, D.S. Chen, M. Green, C. Derleth, G.D. Fine, P.S. Hegde, R. Bourgon, T. Powles, TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells, Nature, 554 (2018) 544-548.
[16] J.J. de Jong, Y. Liu, A.G. Robertson, R. Seiler, C.S. Groeneveld, M.S. van der Heijden, J.L. Wright, J. Douglas, M. Dall'Era, S.J. Crabb, B.W.G. van Rhijn, K.E.M. van Kessel, E. Davicioni, M.A.A. Castro, Y. Lotan, E.C. Zwarthoff, P.C. Black, J.L. Boormans, E.A. Gibb, Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis, Genome Med, 11 (2019) 60.
[17] J.A. Efstathiou, K.W. Mouw, E.A. Gibb, Y. Liu, C.L. Wu, M.R. Drumm, J.B. da Costa, M. du Plessis, N.Q. Wang, E. Davicioni, F.Y. Feng, R. Seiler, P.C. Black, W.U. Shipley, D.T. Miyamoto, Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer, Eur Urol, 76 (2019) 59-68.
[18] R. Seiler, E.A. Gibb, N.Q. Wang, H.Z. Oo, H.M. Lam, K.E. van Kessel, C.S. Voskuilen, B. Winters, N. Erho, M.M. Takhar, J. Douglas, F. Vakar-Lopez, S.J. Crabb, B.W.G. van Rhijn, E.E. Fransen van de Putte, E.C. Zwarthoff, G.N. Thalmann, E. Davicioni, J.L. Boormans, M. Dall'Era, M.S. van der Heijden, J.L. Wright, P.C. Black, Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer, Clin Cancer Res, 25 (2019) 5082-5093.
[19] B.N. Song, S.K. Kim, J.Y. Mun, Y.D. Choi, S.H. Leem, I.S. Chu, Identification of an immunotherapy-responsive molecular subtype of bladder cancer, EBioMedicine, 50 (2019) 238-245.
[20] L. Xia, X. Su, J. Shen, Q. Meng, J. Yan, C. Zhang, Y. Chen, H. Wang, M. Xu, ANLN functions as a key candidate gene in cervical cancer as determined by integrated bioinformatic analysis, Cancer Manag Res, 10 (2018) 663-670.
[21] P. Charoentong, F. Finotello, M. Angelova, C. Mayer, M. Efremova, D. Rieder, H. Hackl, Z. Trajanoski, Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade, Cell Rep, 18 (2017) 248-262.
[22] Y. Şenbabaoğlu, R.S. Gejman, A.G. Winer, M. Liu, E.M. Van Allen, G. de Velasco, D. Miao, I. Ostrovnaya, E. Drill, A. Luna, N. Weinhold, W. Lee, B.J. Manley, D.N. Khalil, S.D. Kaffenberger, Y. Chen, L. Danilova, M.H. Voss, J.A. Coleman, P. Russo, V.E. Reuter, T.A. Chan, E.H. Cheng, D.A. Scheinberg, M.O. Li, T.K. Choueiri, J.J. Hsieh, C. Sander, A.A. Hakimi, Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures, Genome Biol, 17 (2016) 231.
[23] A. Rody, T. Karn, C. Liedtke, L. Pusztai, E. Ruckhaeberle, L. Hanker, R. Gaetje, C. Solbach, A. Ahr, D. Metzler, M. Schmidt, V. Müller, U. Holtrich, M. Kaufmann, A clinically relevant gene signature in triple negative and basal-like breast cancer, Breast Cancer Res, 13 (2011) R97.
[24] E. Azizi, A.J. Carr, G. Plitas, A.E. Cornish, C. Konopacki, S. Prabhakaran, J. Nainys, K. Wu, V. Kiseliovas, M. Setty, K. Choi, R.M. Fromme, P. Dao, P.T. McKenney, R.C. Wasti, K. Kadaveru, L. Mazutis, A.Y. Rudensky, D. Pe'er, Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment, Cell, 174 (2018) 1293-1308.e1236.
[25] S. Hänzelmann, R. Castelo, J. Guinney, GSVA: gene set variation analysis for microarray and RNA-seq data, BMC Bioinformatics, 14 (2013) 7.
[26] D.A. Barbie, P. Tamayo, J.S. Boehm, S.Y. Kim, S.E. Moody, I.F. Dunn, A.C. Schinzel, P. Sandy, E. Meylan, C. Scholl, S. Frohling, E.M. Chan, M.L. Sos, K. Michel, C. Mermel, S.J. Silver, B.A. Weir, J.H. Reiling, Q. Sheng, P.B. Gupta, R.C. Wadlow, H. Le, S. Hoersch, B.S. Wittner, S. Ramaswamy, D.M. Livingston, D.M. Sabatini, M. Meyerson, R.K. Thomas, E.S. Lander, J.P. Mesirov, D.E. Root, D.G. Gilliland, T. Jacks, W.C. Hahn, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, 462 (2009) 108-112.
[27] https:// portal.gdc.cancer.gov/
[28] A. Mayakonda, D.C. Lin, Y. Assenov, C. Plass, H.P. Koeffler, Maftools: efficient and comprehensive analysis of somatic variants in cancer, Genome Res, 28 (2018) 1747-1756.
[29]https://tcga.xenahubs.net/download/TCGA.BLCA.sampleMap/Gistic2_CopyNumber_Gistic2_all_thresholded.by_genes.gz
[30] M. Ayers, J. Lunceford, M. Nebozhyn, E. Murphy, A. Loboda, D.R. Kaufman, A. Albright, J.D. Cheng, S.P. Kang, V. Shankaran, S.A. Piha-Paul, J. Yearley, T.Y. Seiwert, A. Ribas, T.K. McClanahan, IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade, J Clin Invest, 127 (2017) 2930-2940.
[31] https://tcga.xenahubs.net/download/TCGA.BLCA.sampleMap/HumanMethylation450.gz
[32] A.E. Teschendorff, F. Marabita, M. Lechner, T. Bartlett, J. Tegner, D. Gomez-Cabrero, S. Beck, A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data, Bioinformatics, 29 (2013) 189-196.
[33] Y. Tian, T.J. Morris, A.P. Webster, Z. Yang, S. Beck, A. Feber, A.E. Teschendorff, ChAMP: updated methylation analysis pipeline for Illumina BeadChips, Bioinformatics, 33 (2017) 3982-3984.
[34] L.A. Williams, L. Mills, A.J. Hooten, E. Langer, M. Roesler, A.L. Frazier, M. Krailo, H.H. Nelson, J. Bestrashniy, J.F. Amatruda, J.N. Poynter, Differences in DNA methylation profiles by histologic subtype of paediatric germ cell tumours: a report from the Children's Oncology Group, Br J Cancer, 119 (2018) 864-872.
[35] J. Reimand, R. Isserlin, V. Voisin, M. Kucera, C. Tannus-Lopes, A. Rostamianfar, L. Wadi, M. Meyer, J. Wong, C. Xu, D. Merico, G.D. Bader, Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap, Nat Protoc, 14 (2019) 482-517.
[36] http://bioinformatics.psb.ugent.be/webtools/Venn/
[37] G. Yu, L.G. Wang, Y. Han, Q.Y. He, clusterProfiler: an R package for comparing biological themes among gene clusters, OMICS, 16 (2012) 284-287.
[38] Z. Liu, M. Li, X. Fang, L. Shen, W. Yao, Z. Fang, J. Chen, X. Feng, Hu, Z. Zeng, C. Lin, J. Weng, Y. Lai, G. Yi, Identification of surrogate prognostic biomarkers for allergic asthma in nasal epithelial brushing samples by WGCNA, J Cell Biochem, 120 (2019) 5137-5150.
[39] https:// string-db.org/
[40] D. Szklarczyk, A.L. Gable, D. Lyon, A. Junge, S. Wyder, J. Huerta-Cepas, M. Simonovic, N.T. Doncheva, J.H. Morris, P. Bork, L.J. Jensen, C.V. Mering, STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets, Nucleic Acids Res, 47 (2019) D607-D613.
[41] S.C. Lemon, J. Roy, M.A. Clark, P.D. Friedmann, W. Rakowski, Classification and regression tree analysis in public health: methodological review and comparison with logistic regression, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine, 26 (2003) 172-181.
[42] B. Farhood, M. Najafi, K. Mortezaee, CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review, J Cell Physiol, 234 (2019) 8509-8521.
[43] A. Garcia-Diaz, D.S. Shin, B.H. Moreno, J. Saco, H. Escuin-Ordinas, G.A. Rodriguez, J.M. Zaretsky, L. Sun, W. Hugo, X. Wang, G. Parisi, C.P. Saus, D.Y. Torrejon, T.G. Graeber, B. Comin-Anduix, S. Hu-Lieskovan, R. Damoiseaux, R.S. Lo, A. Ribas, Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression, Cell reports, 19 (2017) 1189-1201.
[44] S. Maleki Vareki, High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors, Journal for immunotherapy of cancer, 6 (2018) 157.
[45] E. Ahlen Bergman, C.A. Hartana, M. Johansson, L.B. Linton, S. Berglund, M. Hyllienmark, C. Lundgren, B. Holmstrom, K. Palmqvist, J. Hansson, F. Alamdari, Y. Huge, F. Aljabery, K. Riklund, M.E. Winerdal, D. Krantz, A.A. Zirakzadeh, P. Marits, L.K. Sjoholm, A. Sherif, O. Winqvist, Increased CD4(+) T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients, Clin Epigenetics, 10 (2018) 102.
[46] R.J. Akhurst, A. Hata, Targeting the TGFβ signalling pathway in disease, Nature reviews. Drug discovery, 11 (2012) 790-811.
[47] M.Y. Teo, K. Seier, I. Ostrovnaya, A.M. Regazzi, B.E. Kania, M.M. Moran, C.K. Cipolla, M.J. Bluth, J. Chaim, H. Al-Ahmadie, A. Snyder, M.I. Carlo, D.B. Solit, M.F. Berger, S. Funt, J.D. Wolchok, G. Iyer, D.F. Bajorin, M.K. Callahan, J.E. Rosenberg, Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 (2018) 1685-1694.
[48] R.F. Sweis, S. Spranger, R. Bao, G.P. Paner, W.M. Stadler, G. Steinberg, T.F. Gajewski, Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer, Cancer immunology research, 4 (2016) 563-568.
[49] N.R. Maimela, S. Liu, Y. Zhang, Fates of CD8+ T cells in Tumor Microenvironment, Comput Struct Biotechnol J, 17 (2019) 1-13.
[50] C.H. Chang, J.D. Curtis, L.B. Maggi, Jr., B. Faubert, A.V. Villarino, D. O'Sullivan, S.C. Huang, G.J. van der Windt, J. Blagih, J. Qiu, J.D. Weber, E.J. Pearce, R.G. Jones, E.L. Pearce, Posttranscriptional control of T cell effector function by aerobic glycolysis, Cell, 153 (2013) 1239-1251.
[51] E.S. Knudsen, S.C. Pruitt, P.A. Hershberger, A.K. Witkiewicz, D.W. Goodrich, Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy, Trends in Cancer, 5 (2019) 308-324.
[52] G. Zhu, L. Pei, Y. Li, X. Gou, EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients, Aging, 12 (2020) 2132-2141.
[53] R. Csepanyi-Komi, E. Wisniewski, B. Bartos, P. Levai, T. Nemeth, B. Balazs, A.R. Kurz, S. Bierschenk, M. Sperandio, E. Ligeti, Rac GTPase Activating Protein ARHGAP25 Regulates Leukocyte Transendothelial Migration in Mice, Journal of immunology (Baltimore, Md. : 1950), 197 (2016) 2807-2815.
[54] R. Csepanyi-Komi, G. Sirokmany, M. Geiszt, E. Ligeti, ARHGAP25, a novel Rac GTPase-activating protein, regulates phagocytosis in human neutrophilic granulocytes, Blood, 119 (2012) 573-582.
[55] L. Tao, Y. Zhu, Y. Gu, J. Zheng, J. Yang, ARHGAP25: A negative regulator of colorectal cancer (CRC) metastasis via the Wnt/beta-catenin pathway, Eur J Pharmacol, 858 (2019) 172476.
[56] K. Xu, B. Liu, Y. Ma, The tumor suppressive roles of ARHGAP25 in lung cancer cells, Onco Targets Ther, 12 (2019) 6699-6710.
[57] Y.F. Gao, X.Y. Mao, T. Zhu, C.X. Mao, Z.X. Liu, Z.B. Wang, L. Li, X. Li, J.Y. Yin, W. Zhang, H.H. Zhou, Z.Q. Liu, COL3A1 and SNAP91: novel glioblastoma markers with diagnostic and prognostic value, Oncotarget, 7 (2016) 70494-70503.
[58] F. Pan, M. Chen, X.Y. Song, J.D. Yang, MicroRNA-301b and its target gene synaptosome-associated protein 91 as important modulators in esophageal cancer: functional experiments, Anticancer Drugs, 31 (2020) 411-422.
[59] Y. Sun, G. Chen, J. He, Z.G. Huang, S.H. Li, Y.P. Yang, L.Y. Zhong, S.F. Ji, Y. Huang, X.H. Chen, M.L. He, H. Wu, Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer, Bioengineered, 12 (2021) 325-340.
[60] J.T. Lee, S.D. Lee, J.Z. Lee, M.K. Chung, H.K. Ha, Expression analysis and clinical significance of CXCL16/CXCR6 in patients with bladder cancer, Oncol Lett, 5 (2013) 229-235.
[61] G. Xiao, X. Wang, J. Wang, L. Zu, G. Cheng, M. Hao, X. Sun, Y. Xue, J. Lu, J. Wang, CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms, Oncotarget, 6 (2015) 14165-14178.
[62] R. Singh, N. Kapur, H. Mir, N. Singh, J.W. Lillard, Jr., S. Singh, CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering, Oncotarget, 7 (2016) 7343-7353.
[63] J.J. Jin, F.X. Dai, Z.W. Long, H. Cai, X.W. Liu, Y. Zhou, Q. Hong, Q.Z. Dong, Y.N. Wang, H. Huang, CXCR6 predicts poor prognosis in gastric cancer and promotes tumor metastasis through epithelial-mesenchymal transition, Oncology reports, 37 (2017) 3279-3286.
[64] J.C. Mossanen, M. Kohlhepp, A. Wehr, O. Krenkel, A. Liepelt, A.A. Roeth, D. Mockel, F. Heymann, T. Lammers, N. Gassler, J. Hermann, J. Jankowski, U.P. Neumann, T. Luedde, C. Trautwein, F. Tacke, CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4(+) T-Cell-Dependent Control of Senescence, Gastroenterology, 156 (2019) 1877-1889 e1874.
[65] S.A. Rosenberg, J.C. Yang, D.E. White, S.M. Steinberg, Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response, Annals of surgery, 228 (1998) 307-319.
[66] S.A. Rosenberg, IL-2: the first effective immunotherapy for human cancer, Journal of immunology (Baltimore, Md. : 1950), 192 (2014) 5451-5458.
[67] M. Ahmadzadeh, S.A. Rosenberg, IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients, Blood, 107 (2006) 2409-2414.
[68] S.D. Barth, J.J. Schulze, T. Kühn, E. Raschke, A. Hüsing, T. Johnson, R. Kaaks, S. Olek, Treg-Mediated Immune Tolerance and the Risk of Solid Cancers: Findings From EPIC-Heidelberg, Journal of the National Cancer Institute, 107 (2015).
[69] H. Imai, M. Saio, K. Nonaka, T. Suwa, N. Umemura, G.F. Ouyang, J. Nakagawa, H. Tomita, S. Osada, Y. Sugiyama, Y. Adachi, T. Takami, Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma, Cancer science, 98 (2007) 416-423.
[70] Z. Sun, Z. Ren, K. Yang, Z. Liu, S. Cao, S. Deng, L. Xu, Y. Liang, J. Guo, Y. Bian, H. Xu, J. Shi, F. Wang, Y.X. Fu, H. Peng, A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8(+) T-cell response and effective tumor control, Nat Commun, 10 (2019) 3874.
[71] Y. Jounaidi, J.F. Cotten, K.W. Miller, S.A. Forman, Tethering IL2 to Its Receptor IL2Rbeta Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells, Cancer Res, 77 (2017) 5938-5951.
[72] K. Nika, C. Soldani, M. Salek, W. Paster, A. Gray, R. Etzensperger, L. Fugger, P. Polzella, V. Cerundolo, O. Dushek, T. Höfer, A. Viola, O. Acuto, Constitutively active Lck kinase in T cells drives antigen receptor signal transduction, Immunity, 32 (2010) 766-777.
[73] U. Bommhardt, B. Schraven, L. Simeoni, Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy, Int J Mol Sci, 20 (2019).
[74] Y. Zhang, D.H. Ou, D.W. Zhuang, Z.F. Zheng, M.E. Lin, In silico analysis of the immune microenvironment in bladder cancer, BMC Cancer, 20 (2020) 265.
[75] A.L. Goldberg, M. Gaczynska, E. Grant, M. Michalek, K.L. Rock, Functions of the proteasome in antigen presentation, Cold Spring Harbor symposia on quantitative biology, 60 (1995) 479-490.
[76] D. de Verteuil, T.L. Muratore-Schroeder, D.P. Granados, M.H. Fortier, M.P. Hardy, A. Bramoullé, E. Caron, K. Vincent, S. Mader, S. Lemieux, P. Thibault, C. Perreault, Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules, Molecular & cellular proteomics : MCP, 9 (2010) 2034-2047.
[77] N. Aptsiauri, T. Cabrera, A. Garcia-Lora, M.A. Lopez-Nevot, F. Ruiz-Cabello, F. Garrido, MHC class I antigens and immune surveillance in transformed cells, International review of cytology, 256 (2007) 139-189.
[78] A. Rouette, A. Trofimov, D. Haberl, G. Boucher, V.P. Lavallee, G. D'Angelo, J. Hebert, G. Sauvageau, S. Lemieux, C. Perreault, Expression of immunoproteasome genes is regulated by cell-intrinsic and -extrinsic factors in human cancers, Sci Rep, 6 (2016) 34019.